oseltamivir has been researched along with Liver Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, CC; Hsiao, MH; Hsu, TC; Huang, PJ; Tzang, BS; Yow, JL | 1 |
| Abdulkhalek, S; Allison, S; Ellis, JP; Haxho, F; Hrynyk, M; Neufeld, RJ; Steele, JA; Szewczuk, MR | 1 |
| Shi, D; Song, X; Yan, B; Yang, D; Yang, J | 1 |
3 other study(ies) available for oseltamivir and Liver Neoplasms
| Article | Year |
|---|---|
Potential of antiviral drug oseltamivir for the treatment of liver cancer.
Topics: Animals; Antiviral Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Female; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Oseltamivir; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma.
Topics: Absorbable Implants; Angiogenesis Inhibitors; Animals; Antigens, CD; Cadherins; Carcinoma; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Drug Implants; Interleukin Receptor Common gamma Subunit; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Mice, Knockout; Neovascularization, Pathologic; Oseltamivir; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Polyethylene Glycols; Solubility; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Clopidogrel; Dose-Response Relationship, Drug; Female; Hepatocytes; Humans; Interleukin-6; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oseltamivir; Platelet Aggregation Inhibitors; RNA, Messenger; Ticlopidine | 2007 |